Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study
SGLT2i use in patients with stage 4 cardiovascular-kidney-metabolic syndrome was associated with reduced hazards of MACEs, MAKEs, and all-cause death, supporting the cardiovascular and renal benefits in this population.
Authors
- Zeyuan Fan (ORCID: https://orcid.org/0000-0001-8923-0141)
- Bing Xiao (ORCID: https://orcid.org/0000-0001-9526-4575)
- Yuntao Li (ORCID: https://orcid.org/0000-0001-8788-7537)
- Tao Liu (ORCID: https://orcid.org/0000-0002-7556-2337)
- He Chang
Institutions
- Aviation General Hospital (CN)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1161/jaha.124.040382
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29